Drugs / Adipose derived stromal cells
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02375802 | Jul 2015 → Dec 2027 expected | decubitus ulcer | Mayo Clinic | Enrolling by invitation | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04711200 | Apr 2024 → Apr 2027 expected | Lyell syndrome, Stevens-Johnson syndrome/toxic epidermal necrolysis overlap syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05079243 | Jun 2021 → Dec 2022 | — | Stemform | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose derived stromal cells | “autologous ex-vivo expanded adipose-derived stromal cells (ASCs)” NCT05079243 ↗ |
| Known as | ASCs | “This pilot study of 12 patients will test the safety and efficacy of applying autologous, adipose-derived stromal cells (ASCs), uncultured, on a Stage III or IV pressure ulcer...” NCT02375802 ↗1“autologous ex-vivo expanded adipose-derived stromal cells (ASCs)” NCT05079243 ↗ |
| Modality | Cell therapy | “adipose-derived stromal cells” NCT05079243 ↗ |
| Route | Intravenous | “Adipose derived stromal cells intravenously injected” NCT04711200 ↗ |